Small-molecule CBLB inhibitor abolishes EGFR ubiquitination, reduces receptor endocytosis, and diminishes cell motility signaling
Proceedings of the National Academy of Sciences · 31.03.2026 · 123 (13)
DOI: 10.1073/pnas.2524664123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 27.03.2026. Verfasst von Itziar Pinilla-Macua und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261. Hauptthemen laut MEDLINE: ErbB Receptors, Endocytosis, Proto-Oncogene Proteins c-cbl, Ubiquitination. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, HHS | NIH | National Cancer Institute (NCI).
Abstract (Originalsprache)
Endocytosis of the epidermal growth factor receptor (EGFR) is considered a key regulator of the receptor signaling activity. However, the molecular mechanisms underlying EGFR endocytosis are incompletely understood. Although ligand-induced ubiquitination of EGFR is known to promote its endocytic trafficking, the importance of EGFR ubiquitination in clathrin-mediated endocytosis, the primary physiological route of EGFR internalization, remains debated, and the relative contributions of ubiquitination-dependent and -independent mechanisms are not defined. Hence, we used NX-1013, a small-molecule inhibitor of the Casitas B-lineage lymphoma-b (CBLB) E3 ubiquitin ligase, to dissect the role of EGFR ubiquitination in its endocytic trafficking and signaling. Strikingly, brief treatment with NX-1013 completely abolished EGF-induced EGFR ubiquitination, demonstrating that this process is exclusively mediated by the closely related CBLB and CBL ligases. NX-1013 inhibited clathrin-mediated internalization of activated EGFR by 60 to 70%. The remaining, ubiquitination-independent internalization required EGFR kinase activity, was highly clathrin-dependent, and was significantly impaired by depletion of the AP-2 clathrin adaptor complex. Interestingly, inhibition of CBLs and EGFR endocytosis by NX-1013 did not affect major downstream signaling pathways in human oral squamous cell carcinoma cells, with the exception of Rac1 activation and EGFR-dependent cell migration, both of which were suppressed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261.
- Nurix Therapeutics, Inc., Brisbane, CA 94005.
ORCID-Profile: Itziar Pinilla-Macua, Ratul Mukerji, Alexander Sorkin
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- HHS | NIH | National Cancer Institute (NCI)
- HHS | NIH | National Institute of General Medical Sciences (NIGMS)
Zitieren
APA
Pinilla-Macua, I., Mukerji, R., Cohen, F., & Sorkin, A. (2026). Small-molecule CBLB inhibitor abolishes EGFR ubiquitination, reduces receptor endocytosis, and diminishes cell motility signaling. Proceedings of the National Academy of Sciences, 123(13). https://doi.org/10.1073/pnas.2524664123
Vancouver
Pinilla-Macua I, Mukerji R, Cohen F, Sorkin A. Small-molecule CBLB inhibitor abolishes EGFR ubiquitination, reduces receptor endocytosis, and diminishes cell motility signaling. Proceedings of the National Academy of Sciences. 2026;123(13). doi:10.1073/pnas.2524664123
BibTeX
@article{PinillaMacua2026,
author = {Pinilla-Macua, Itziar and Mukerji, Ratul and Cohen, Frederick and Sorkin, Alexander},
title = {Small-molecule CBLB inhibitor abolishes EGFR ubiquitination, reduces receptor endocytosis, and diminishes cell motility signaling},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {13},
doi = {10.1073/pnas.2524664123}
}
EUVIMED